- Home
- SGMO
as 11-21-2024 4:00pm EST
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 180.5M | IPO Year: | 2000 |
| Target Price: | $7.00 | AVG Volume (30 days): | 11.1M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $3.18 | Next Earning Date: | 11-12-2024 |
| Revenue: | $52,291,000 | Revenue Growth: | -74.04% |
| Revenue Growth (this year): | -72.19% | Revenue Growth (next year): | 71.79% |
Latest Sangamo Therapeutics Inc. News
SGMO Breaking Stock News: Dive into SGMO Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Simply Wall St.
7 days ago
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
8 days ago
Q3 2024 Sangamo Therapeutics Inc Earnings Call
GuruFocus.com
9 days ago
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Zacks
9 days ago
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates
Associated Press Finance
9 days ago
Sangamo: Q3 Earnings Snapshot
Business Wire
9 days ago
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Business Wire
17 days ago
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Compare SGMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMO Sangamo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.